PredictTB is a large-scale clinical study that receives both international and national as well as public and private funding from Europe, South Africa, China, and the US. LINQ is managing the European funding by the EDCTP, headed by our long-time collaborator Prof. Gerhard Walzl, and leads the Project Management Work Package. The PredictTB consortium carries out a large-scale clinical study in China and South Africa to find and validate biomarkers that can identify patients with drug-sensitive pulmonary tuberculosis who can be cured with shorter treatment. Further, the group aims at developing a point-of-care test that helps decide which patients are eligible for shortened treatment.
Central topics of discussion during the annual meeting were the ongoing analysis of samples and data collected in the clinical study and the progress of the development of the point-of-care test.
PredictTB will come to an end in July 2022. Diligent work by the consortium over the past year has put the group in a great position to produce valuable results during the final months of the project. For a more detailed overview of how LINQ has supported the project over the past years, check out the PredictTB showcase page here.